podcast download here
Joshua Allen, Senior Vice President of Research and Development at Oncoceutics joins us to explain a novel group of compounds called imipridones that he helped to create which target specific mutations in an wide array of cancer types. ONC201, the first that he personally discovered, is now being used in clinical trials for previously untreatable varieties of pediatric brain cancer. This new development in precision medicine is bringing hope to the worst of the worst, DIPG, diffuse intrinsic pontine glioma, and other deadly pediatric and adult CNS tumors.
A modestly sized company, Oncoceutics maintains its commitment to scientific discovery and saving lives as its primary purpose.
